Develops treatments for neurological disorders and age-related diseases, focusing on innovative therapies.
Renovaro Inc., a biotechnology company in the pre-clinical stage, focuses on advancing pharmaceutical and biological products designed to address critical medical challenges such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer within the United States.
The company's innovative product pipeline includes several promising candidates. Among these are RENB-HV-01, aimed at developing an autologous treatment for HIV, RENB-HV-12, a therapeutic vaccine targeting HIV, and RENB-HB-01, a gene therapy designed for the curative treatment of HBV.
Renovaro Inc. is also actively developing RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine intended for pancreatic cancer, and RENB-DC-12-XX, targeting other solid tumors using similar technology. Additionally, the company is advancing RENB-HV-21, focusing on HIV treatment through allogeneic natural killer (NK) and gamma delta T-cells. With strategic partnerships established with institutions such as the University of California and Fred Hutchinson Cancer Research Center, Renovaro Inc. is poised to drive forward innovative solutions in biomedicine. The company, formerly known as Renovaro Biosciences Inc., rebranded to Renovaro Inc. in February 2024 and is headquartered in Los Angeles, California.